Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oklahoma for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oklahoma only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oklahoma (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Caleb Scheckel (NPI 1447606348)

Field	Value
Entity Type	Individual
Organization	Caleb Scheckel
Address	12697 E 51st St
City	Tulsa
State	OK
ZIP	74146
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 10, 2016

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

CALEB SCHECKEL (Hematology & Oncology Physician in TULSA, OK) profiles as an oncology infusion practice based on the revenue mix: high-revenue biologic/immunotherapy codes appear at the top of the Medicare list, led by J9271 ($301K), J9144 ($205.2K) and J9299 ($191K), and the presence of chemotherapy/infusion codes such as 96413 and 96367. The code set also includes supportive-care agents (granisetron J1627, immune globulin J1569, denosumab J0897) and bundled imaging/lab work, consistent with an integrated clinic that delivers systemic cancer therapy and onsite diagnostics.

Revenue concentration is notable: the precomputed top-3 Medicare codes (J9271, J9144, J9299) together account for 47.8% of this provider's total Medicare revenue, against a reported total Medicare lifetime revenue of $1.6M. This concentration indicates that a small set of high-cost biologic infusions disproportionately drive the practice’s Medicare receipts.

Payer mix is effectively single-payer at the claims level: the profile shows Total Medicare revenue of $1.6M and no Medicaid billing on file. The lack of Medicaid activity suggests the provider’s Medicare business drives volume and revenue exposure, which has implications for contract negotiation and network coverage strategies in markets where Medicaid participation matters.

Despite high absolute revenue from certain biologics, the provider’s competitive standing on those top drugs is modest nationally: J9271 ranks #1520 of 1841 (16th percentile; typical, unremarkable volume), J9144 ranks #467 of 615 (23th percentile; typical, unremarkable volume), and J9299 ranks #407 of 505 (19th percentile; typical, unremarkable volume). These ranks imply routine presence in immunotherapy use but not a dominant national position for individual agents.

Billing intensity for office visits is an outlier relative to peers: 99215 appears as an extreme outlier with 553 claims, $127 avg paid/claim and $70.2K revenue (4.8% of Medicare revenue), ranking #1506 of 145531 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). This suggests an unusually high proportion of high-complexity evaluation-and-management visits, which may reflect complex patient management, longer visit times, or a coding mix skewed toward higher-level E&M.

Ancillary diagnostics and procedure volumes are relatively concentrated and above typical peer levels for several lab codes, supporting an on-site diagnostics model: 85055 is notably above typical national volume (315 claims, $11K revenue) and 36415 ranks in the 98th percentile; additional lab panels such as 80053 ($14.9K, 97th percentile) and 83735 ($10.4K, 96th percentile) also show high national ranks. Imaging appears present but not dominant (78815 and 78816 are at mid-percentiles), indicating diagnostics are an important but not primary revenue source.

Supportive and infusion-related codes show a diversified set of lower-revenue contributors that round out the clinical service mix: J1569 ($66.9K), J1627 ($40.5K), J0897 ($30.8K) and infusion add-on 96367 ($10.3K) indicate routine supportive care, antiemetic use, IVIG administration, and bone-health therapy alongside oncology infusions. These items collectively reinforce the clinical picture of a practice that provides both primary infusion therapy and ancillary supportive services.

The provider has been enumerated since 2016-05-10 (~10 years ago), indicating an established presence in the market with cumulative Medicare lifetime revenue of $1.6M reported on file. Tenure combined with the observed billing profile—concentrated biologic infusion revenue plus unusually high 99215 volume—signals a stable, established oncology practice focused on complex outpatient cancer care rather than broad Medicaid-covered services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

87 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	7,000	$40	$301K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,400	$40	$205.2K
J9299	Injection, nivolumab, 1 mg	7,960	$20	$191K
J9022	Injection, atezolizumab, 10 mg	1,780	$60	$113.7K
J1930	Injection, lanreotide, 1 mg	2,520	$40	$110.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	550	$130	$70.2K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,390	$30	$66.9K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	60	$1,060	$61.2K
J1627	Injection, granisetron, extended-release, 0.1 mg	8,100	$10	$40.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	360	$90	$32.9K

Showing 1–10 of 87

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 87 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oklahoma Distribution

Caleb Scheckel — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oklahoma

Full comparison — all codes billed, vs. state median

87 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	10	10,600	$40	$466.9K
J9299	8	10	14,050	$20	$324.4K
J9144	6	10	6,480	$40	$248.5K
J1930	4	10	2,910	$40	$137.2K
J1569	10	20	3,670	$30	$125.8K
J9022	2	10	1,960	$60	$122.8K
J0897	47	70	2,130	$20	$91.2K
Q5119	3	10	1,280	$20	$31.1K
J1627	4	10	6,100	$1	$30.1K
78815	52	80	80	$230	$29.2K

Showing 1–10 of 87

Related Providers

Other providers that share a Tax Identification Number (TIN) with Caleb Scheckel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mayo Collaborative Services, Inc	MN	Clinical Medical Laboratory	$6.5M	$39.2M
Mayo Clinic Arizona	AZ	General Acute Care Hospital	$0	$12.5M
Sachin Mehta	AZ	Retina Specialist (Ophthalmology) Physician	$4.4M	$11.8K
Mayo Clinic Arizona	AZ	Clinical Medical Laboratory	$3.1M	$76.8K
Grenville Jones	ME	Therapeutic Radiology Physician	$2.8M	$0
Scott Cole	OK	Hematology & Oncology Physician	$2.3M	$0
Charles Taylor	OK	Hematology & Oncology Physician	$2.3M	$0
Ryan Robetorye	AZ	Clinical Pathology/Laboratory Medicine Physician	$2.3M	$0
Mark Olsen	OK	Hematology & Oncology Physician	$2.2M	$0
Paul Zito	OK	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as Caleb Scheckel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Option 1 Nutrition Solutions LLC	OK	Durable Medical Equipment & Medical Supplies	$0	$18.8M
Regional Medical Laboratory, Inc	OK	Clinical Medical Laboratory	$0	$17.6M
Labcorp Oklahoma, Inc.	OK	Clinical Medical Laboratory	$6.8M	$7.8M
Access Pain Solutions	OK	Pain Medicine Physician	$0	$13.1M
Osu Center For Health Sciences	OK	Medical Specialty Clinic/Center	$0	$10.5M
Advanced Pediatric Care	OK	Durable Medical Equipment & Medical Supplies	$0	$4.9M
Asm LLC	OK	Customized Equipment (DME)	$0	$4.7M
Pathology Laboratory Associates, Inc.	OK	Anatomic Pathology & Clinical Pathology Physician	$22.2K	$3.9M
Sleep Management, L.L.C.	OK	Oxygen Equipment & Supplies (DME)	$0	$3.6M
Tulsa Bone & Joint Associates PC	OK	Orthopaedic Surgery Physician	$0	$3M

Caleb Scheckel — Billing Profile & Reimbursement Data

Sign up for Caleb Scheckel — Billing Profile & Reimbursement Data policy alerts

Caleb Scheckel — Billing Profile & Reimbursement Data

Sign up for Caleb Scheckel — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References